tamsulosin has been researched along with Diabetic Glomerulosclerosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kida, J; Mashimo, H; Matsuya, H; Okada, H; Otsuki, T; Sekido, N; Wakamatsu, D | 1 |
| Hu, W; Sun, C; Sun, L; Zhang, L; Zhou, S | 1 |
2 other study(ies) available for tamsulosin and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
EP2 and EP3 receptors as therapeutic targets for underactive bladder/detrusor underactivity due to diabetic cystopathy in a type 1 diabetic rat model.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Cholinesterase Inhibitors; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Male; Pyridinium Compounds; Rats, Sprague-Dawley; Receptors, Prostaglandin E, EP2 Subtype; Receptors, Prostaglandin E, EP3 Subtype; Tamsulosin; Thiazoles; Urinary Bladder, Underactive; Urological Agents | 2020 |
Tamsulosin attenuates high glucose- induced injury in glomerular endothelial cells.
Topics: Cytokines; Diabetic Nephropathies; Endothelial Cells; Fibrosis; Glucose; Humans; Inflammation; Kidney Glomerulus; Oxidative Stress; Tamsulosin | 2021 |